Dysfunctional uterine bleeding
Adult: 60 mg twice a wk for the 1st 12 wk and then 60 mg once a wk for up to next 12 wk.
Adult: Take 1 tablet (30 mg) twice a wk for the 1st 12 wk then 1 tablet (30 mg) once a wk from 13th wk onwards. Take 1st tablet on the 1st day of menstrual cycle. Follow dose irrespective of menstrual periods.
|Polycystic ovarian disease, cervical hyperplasia, recent history of jaundice or hepatic impairment, severe allergic states, TB, renal impairment. Pregnancy and lactation.
Warnings / Precautions
|Women who desire to be pregnant should discontinue taking the drug.
Mechanism of Actions
|Ormeloxifene acts on oestrogen receptors. It has a weak estrogenic and potent antiestrogenic actions. It is expected to exert a contraceptive effect and normalise the bleeding from uterine cavity by regularising the expression of oestrogen receptors on the endometrium. As a contraceptive, it prevents proliferation and decidualisation of the endometrium, enhances blastocyst formation and slightly increases embryo transport through the oviducts.
Absorption: Well absorbed from the GI tract. Peak serum levels achieved in 4 hr.
Distribution: Widely distributed in tissues. Little affinity to plasma proteins.
Excretion: Terminal half-life: Approx 170 hr.
Ormeloxifene Containing Brands
Ormeloxifene is used in following diseases
Drug - Drug Interactions of Ormeloxifene
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor